Press Release
Replica Analytics Announces New Funding from Nina Capital
Replica Analytics has closed a financing round with Nina Capital. This new funding ...
News
Aetion: Fierce 15 Awards 2021
Amidst unprecedented challenges, adaptability emerged as a key determinant of success for ...
News
SARS-CoV-2 antibodies can protect from reinfection, NCI study suggests
As COVID-19 vaccines start to roll out in the US, research led by the National Cancer ...
Press Release
First RCT-DUPLICATE findings published in Circulation
NEW YORK, December 17, 2020 — Real-world evidence (RWE) studies can offer comparable ...
News
Her Story podcast: Fitting the pieces together with Carolyn Magill
This podcast episode features an interview with Carolyn Magill, the CEO of Aetion, a ...
News
‘Unpredictable pathogen’: New coronavirus study highlights severity of illness
While COVID-19 is commonly associated with symptoms like a loss of smell or taste, a new ...
Press Release
Replica Analytics Data Synthesis Platform Launched to Support Data Transparency and Data Science Globally
Replica Analytics Ltd., a leading provider of privacy protective synthetic data, is proud ...
Press Release
FACIT backs made-in-Ontario data science and medtech innovations through Prospects Oncology Fund
Replica Analytics and Sunnybrook’s Czarnota Lab receive key seed funding to de-risk ...
Press Release
New Funding for Data Synthesis Innovations
Replica Analytics Receives over $1 Million in New Funding for Data Synthesis Innovations ...
Press Release
First Synthetic Health Dataset in Province
Alberta Project Validates First Synthetic Health Dataset in Province Read more
Press Release
Aetion statement on UCSF-led study to inform drug development for COVID-19, future pandemics
NEW YORK, October 15, 2020 — Aetion co-authored a study published today in Science, which ...
News
Health analytics startup expands partnership with global pharma firm
As president and chief operating officer of Mount Sinai Hospital, Dr. David Reich ...
Press Release
UCB and Aetion announce agreement to enhance real-world evidence generation to advance value-based contracts
NEW YORK, Oct. 7, 2020 /PRNewswire/ -- Today, Aetion and UCB announced a new agreement to ...
News
Data-driven approach to COVID-19 requires rigor, transparency
Aetion CEO Carolyn Magill spoke with S&P Global Market Intelligence about the ...
News
MedCity Pivot: Real-world evidence with Carolyn Magill
Arundhati Parmar interviewed Carolyn Magill, CEO of Aetion. They discussed the growing ...
News
Ask the Experts: applications of real-world data during—and beyond—COVID-19
In this ‘Ask the Experts’ feature, explore some of the potential applications of ...
News
Aetion adds another $19M to its Series B to make sense of drug development and treatment data
AlleyWatch caught up with CEO Carolyn Magill to learn more about how the company powers ...
News
Aetion pushes Series B to $82M as pandemic puts real-world evidence under the spotlight
Former FDA chief Scott Gottlieb’s favorite real-world evidence platform is getting a new ...
Press Release
Aetion adds strategic investment from Johnson & Johnson Innovation — JJDC, Inc., EDBI, Greenspring Associates to expand RWE offerings
NEW YORK, August 26, 2020 — Today, Aetion, a health care technology company that delivers ...
News
Aetion, Cegedim Health Data partner on European RWE effort
Outsourcing Pharma writes in July 2020, Aetion and Cegedim Health Data announce plans to ...
News
Aetion, Cegedim form transatlantic real-world data alliance
Health tech companies Aetion and Cegedim have agreed to combine their data platforms, to ...
Press Release
Aetion and Cegedim Health Data announce new partnership to power real-world evidence research in Europe
July 8, 2020 — Today Aetion and Cegedim Health Data announced a new partnership to ...
News
The Cures Act’s second act: Six ways to ensure Congress doubles down on its boldest bet
When the 21st Century Cures Act became law in 2016, the legislation boldly funded the ...
News
Real-world data partnership on COVID-19: US FDA drawn to consistency, diversity of Aetion's datasets
FDA's Amy Abernethy tells the Pink Sheet that initial priorities are likely to include ...